Summary Conjugated linoleic acid (CLA) is a collective term used for fatty acids with a conjugated double bond that are geometrical and positional isomers of linoleic acid. Antiobesity and anti-cancer properties, an immunopotentiation effect, and promotion of bone formation by CLA have been shown in cell culture and animal studies. A mixture of 9c11t-and 10t12c-CLA is now used as a health food supplement after testing in clinical trials. These trials focused on improvement of lipid metabolism by CLA, whereas few studies have examined absorption and metabolism of CLA in humans. In addition, there is no report concerning absorption and metabolism of CLA in Japanese. This study was designed to examine CLA concentration in blood, the elimination rate of CLA, and metabolic differences between 9c11t-CLA and 10t12c-CLA in blood in Japanese who ingested CLA (about 2 g/d, equal weights of 9c11t-CLA and 10t12c-CLA) for 3 wk. Blood samples were collected 1 wk before the 3-wk period, on the first and last days of the period, and 1 wk after the end of the period, and the CLA concentration and distribution in blood were investigated. The CLA concentration in blood was significantly increased by CLA ingestion and reached 36 mol/L. The CLA concentration in blood one week after the intake period was significantly lower than that at the end of CLA intake. The 10t12c-CLA level in plasma decreased faster than that of 9c11t-CLA. This suggests faster metabolism (fatty acid ␤ oxidation) of 10t12c-CLA compared with 9c11t-CLA. Key Words conjugated fatty acid, CLA, conjugated linoleic acid, metabolism, human Conjugated linoleic acid (CLA) is a collective term used for fatty acids with a conjugated double bond that are geometrical and positional isomers of linoleic acid. CLA isomers with conjugated double bonds at positions 7 and 9, 8 and 10, 9 and 11, 10 and 12, and 11 and 13 are known, with the main natural CLA isomer having a 9-cis, 11-trans configuration (9c11t-CLA). Anti-obesity and anti-cancer properties, an immunopotentiation effect, and promotion of bone formation by CLA have been shown in cell culture and animal studies ( 1-4 ) . A mixture of 9c11t-and 10t12c-CLA is now used as a health food supplement after testing in clinical trials ( 5-7 ). These trials focused on improvement of lipid metabolism by CLA, whereas few studies have examined absorption and metabolism of CLA in humans. However, animal studies suggest greater accumulation of 9c11t-CLA than 10t12c-CLA in vivo ( 8-10 ).
ever, animal studies suggest greater accumulation of 9c11t-CLA than 10t12c-CLA in vivo (8) (9) (10) .
Safe and effective use of CLA requires information on absorption and metabolism in humans. In this study, we measured CLA concentrations in blood, the rate of elimination of CLA, metabolic differences between 9c11t-and 10t12c-CLA, and CLA distribution in blood in healthy subjects who ingested CLA (about 2 g/d, equal weights of 9c11t-and 10t12c-CLA) for 3 wk. Blood samples were collected before and after the 3-wk period. The CLA concentration in blood increased after CLA ingestion, and decreased at one week after intake compared with at the end of CLA intake. Furthermore, the level of 10t12c-CLA in plasma decreased faster than that of 9c11t-CLA. There were no significant differences in the CLA distribution in blood.
MATERIALS AND METHODS
Study Protocol. Twenty-four healthy subjects (12 men and 12 women) aged 22.3 Ϯ 0.3 y old with a mean body mass index of 20.2 Ϯ 0.4 kg/m 2 were randomly assigned to a CLA-treated group (6 men and 6 women) or a control group (6 men and 6 women). All subjects were generally healthy, as demonstrated by their medical history and a physical examination. The study was performed with a randomized double-blind placebo-controlled design. The subjects in the CLA group were given capsules containing 2.2 g/d of CLA daily for 3 wk, while those in the control group were given capsules containing 2.0 g/d of linoleic acid (LA). The dosage in this study was decided referring to the previous report of Ireland ( 11 ) . The dosage in the report was about 2 g/ d (equal weights of 9c11t-CLA and 10t12c-CLA) and CLA concentration in blood was measured. Therefore, to compare the change in blood CLA concentration of foreigners and Japanese, a similar dosage was decided for this study. The fatty acid compositions in test supplements are shown in Table 1 . Test supplements were provided by The Nisshin OilliO Group, Ltd. (Yokosuka, Japan). Blood samples (10 mL) were collected after fasting for 12 h at one week before the trial, on the first and last days of the 3-wk trial period, and a week after the last day of the trial (0, 1, 4, and 5 wk, respectively). The study was approved by the Ethics Committee of Tohoku University (Sendai, Japan) and was conducted in compliance with the Helsinki Declaration, as described previously ( 12 ) . All subjects gave written informed consent.
Sample preparation. Blood samples were collected in the morning after 12 h fasting without food ( 12 ) . Venous blood samples of 10 mL were collected in a tube containing 5 mg EDTA-Na. After centrifugation at 1,000 g for 10 min at 4˚C, the supernatant plasma was separated with a pipette. The remaining red blood cells (RBCs) were washed three times with phosphate-buffered saline (PBS) ( 13 ) .
Biochemical analysis. Plasma glucose, triacylglycerol (TG), total cholesterol (TC), phospholipids (PL), LDLcholesterol (LDL-C), HDL-cholesterol (HDL-C), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were determined using commercial kits ( 14 ) .
Preparation of plasma lipoprotein. VLDL, LDL, and HDL were isolated from plasma by ultracentrifugation ( 15 ) . VLDL was isolated by overlaying 1 mL of sample with 500 L of aqueous sodium chloride solution [density ( d ) ϭ 1.006 g/mL] and spinning for 1 h at 16˚C and 1,019,000 g in the outermost row of a Beckman MLA-130 rotor with a Beckman optima max ultracentrifuge (Beckman Coulter Inc., Fullerton, CA). The top 500 L from each tube was collected by aspiration and stored at Ϫ 80˚C. LDL was isolated in a second ultracentrifugation step by overlaying the plasma remaining after VLDL aspiration with sodium bromide solution to produce a final density of 1.063 g/mL and spinning for 1.5 h under the same conditions as those for VLDL isolation. The top 500 L was collected by aspiration. In a further ultracentrifugation step, HDL was isolated by overlaying the plasma remaining after LDL aspiration with sodium bromide solution to produce a final density of 1.21 g/mL and spinning for 2.5 h. The top 500 L was collected by aspiration. Three density fractions of plasma were thus isolated: Ͻ 1.006 g/mL (VLDL), 1.006-1.063 g/mL (LDL), and 1.063-1.21 g/mL (HDL).
Measurement of CLA. Total lipids from plasma, RBCs, VLDL, LDL, HDL, and test supplements were extracted using the Bligh and Dyer procedure ( 16 ) and methylated (along with a known amount of heptadecanoic acid as an internal standard) at room temperature by addition of trimethylsilyldiazomethane (TMSN 2 CH 3 ) for 30 min and sodium methoxide/methanol for 10 min ( 17 , 18 ) . Briefly, total lipids in 900 L of MeOH : CHCl 3 (2 : 7, v : v) were added to 1.3 mmol/L TMSN 2 CH 3 in n -hexane. After standing for 30 min at room temperature, the reaction mixture was dried under a stream of nitrogen gas and the dried residue was dissolved in 1 mol/L sodium methoxide in methanol. After a 10-min incubation at room temperature, the reaction was stopped by adding saturated NaCl solution, and fatty acid methyl esters (FAME) were extracted with n -hexane and subjected to gas chromatography (GC-2014, Shimadzu) using a flame ionization detector and a Supelcowax-10 fused silica capillary column (60 m ϫ 0.32 mm, 0.25 m film thickness) or a CP-Sil 88 fused silica capillary column (50 m ϫ 0.22 mm, 0.2 m film thickness). Helium was used as the carrier gas. The injector and detector temperatures were 200 and 250˚C, respectively, and the column oven temperature was increased by 20˚C/min from 50 to 200˚C and then held constant for 32.5 min. Peak components were identified by comparing their retention times with those of commercial FAME (Funakoshi, Tokyo), and also by analyzing CLA dimethyloxazoline derivatives by GC-EI-MS (GCMS-QP5050A, Shimadzu), as previously described ( 17 ) . For the GC-EI-MS analysis, 4,4-dimethyloxazoline derivatives were prepared from CLA as follows. Total lipids were processed to free fatty acids, and the free fatty acids were mixed with 2-amino-2-methyl-1-propanol. The test tube was purged with nitrogen gas, screw-capped, and heated at 170˚C. After 30 min, the tube was cooled, and a saturated NaCl solution and n -hexane were added, followed by vigorous shaking. After centrifugation, the hexane phase was dried under a stream of nitrogen gas, and the dried residue was then redissolved in an adequate amount of n -hexane. GC-EI-MS was performed using a GC (GC-17A, Shimadzu) equipped with a Supelcowax-10 fused silica capillary column coupled to an EI-MS (GCMS-QP5050A, Shimadzu). Helium was used as the carrier gas. The injector temperature was 200˚C. The oven S ATO K et al. Table 2 . CLA ratio in fatty acid composition (%) and CLA concentration (mol/L) in plasma and RBC. temperature was programmed to match the temperature used in the corresponding GC analysis described above. The temperature of the ion source was 250˚C. Electron impact mass spectra were recorded at 70 eV and analyzed using the CLASS 5000 data system (Shimadzu). The fatty acid compositions of the test supplements are shown in Table 1 . Measurement of CLA using boron trifluoride. Free fatty acids in total lipids from plasma were prepared by adding 0.5 mL of 0.01 mol/L NaOH in dry methanol. Samples were vortexed and flushed with N2 and then placed in a heating block at 60˚C for 15 min. Boron trifluoride (0.75 mL) was added to the mixture and the samples were vortexed and incubated at 60˚C for 15 min. Lipids were extracted three times using 0.5 mL n-hexane. Samples were dried in a vortex evaporator and subjected to GC (19) .
Statistical analysis. Results are expressed as meansϮSE. Data were analyzed by one-way ANOVA followed by inspection of all differences by the Tukey's test.
A difference was considered to be significant at pϽ0.05.
RESULTS

Changes in CLA levels in blood
CLA ratios (% in fatty acid composition) and concentrations (mol/L) in RBCs, plasma, and blood at 1 wk before, on the first and last days of, and 1 wk after the 3-wk period of CLA ingestion (0, 1, 4, and 5 wk, respectively) are shown in Table 2 . The CLA ratios and concentrations in RBCs, plasma, and blood in the CLA group at week 4 (the last day of CLA intake) were significantly higher than those at week 1 (the first day of CLA intake). The 9c11t-18:2 and total CLA levels showed fivefold and eightfold increases, respectively. These levels at week 5 (1 wk after completion of CLA intake) were also significantly higher than those at week 1. 10t12c-18:2 was detected in the CLA group at weeks 4 and 5, but was not detected in the control group. No significant differences in CLA ratios and concentrations were found between weeks 0 and 1 in the CLA group or between any time points in the control group. Change in CLA levels in lipoprotein CLA levels in plasma lipoprotein (VLDL, LDL and HDL) were measured before and after CLA ingestion. The CLA ratios in plasma lipoprotein at weeks 0, 1, 4 and 5 are shown in Table 3 . In the CLA group, the CLA ratios in VLDL, LDL and HDL at week 4 were significantly higher than those at week 1; with increases in 9c11t-18:2 and total CLA of about threefold and fivefold, respectively, in VLDL; threefold and sixfold, respectively, in LDL; and fourfold and sevenfold, respectively, in HDL. The 9c11t-18:2 and total CLA levels in VLDL, LDL and HDL at week 5 were also significantly higher than those at week 1. No significant differences in CLA ratio were found between weeks 0 and 1. 10t12c-18:2 was detected in the CLA group at weeks 4 and 5, but was not detected in the control group. No significant differences in CLA ratios were found in the control group.
CLA distribution in the blood
CLA ratios in RBCs and plasma lipoprotein (VLDL, LDL and HDL) at weeks 0, 1, 4 and 5 are shown in Table  4 . The CLA ratio in RBCs was significantly higher in the CLA group at week 5. The CLA ratio did not differ significantly in the control group at weeks 0, 1, 4 or 5 or in the CLA group at weeks 0, 1 or 4.
Rate of elimination of CLA
To examine the rate of elimination, CLA in RBCs, plasma, VLDL, LDL, and HDL was measured at one week after the last day of CLA intake. The retention of CLA in these blood components was determined by comparison with the CLA levels at week 4 ( Fig. 1) . The retention rate of total CLA in RBCs was 62%, which was significantly higher than the rates of 23%, 20%, 20%, and 25% in plasma, VLDL, LDL, and HDL, respectively. The retention rates of 9c11t-18:2 and 10t12c-18:2 in RBCs were 65% and 58%, respectively, and these were also significantly higher than the rates of 29%, 35%, 
123). Biochemical parameters in plasma
To investigate changes in biochemical parameters in plasma of subjects after CLA intake, plasma collected at weeks 0, 1, 4 and 5 was analyzed. However, no influence of CLA ingestion on the levels of TG, T-CHO, LDL-C, HDL-C, PL, glucose, AST, or ALT was observed (Table  5) .
DISCUSSION
In this study, CLA concentrations in blood were examined in healthy subjects after CLA ingestion to evaluate the metabolism of CLA. The results provided information on the blood CLA concentration after normal eating, the change in CLA concentration caused by CLA ingestion, the CLA distribution in blood, and the CLA concentration at one week after completion of CLA ingestion. A difference in the rate of metabolism of two CLA isomers was shown. These data are important for appropriate use of CLA in humans, and provide the first set of such data in Japanese subjects.
The CLA concentrations in blood were measured at one week before the 3-wk trial intake period, on the first and the last days of the trial, and 1 wk after the end of the trial (0, 1, 4, and 5 wk). The CLA concentration was significantly increased by CLA ingestion and some CLA remained at week 5 ( Table 2 ). The 9c11t-18:2 CLA isomer was detected before CLA intake, but 10t12c-18:2 was not detected. Thus, 10t12c-18:2 may not be present naturally and is not available from a normal diet, whereas 9c11t-18:2 is present and can be obtained from a normal diet.
In this study, the increase in CLA in the plasma after CLA ingestion (about eightfold) was larger than that in previous reports (11, 19, 20) . Furthermore, 10t12c-18:2 was clearly detected in the plasma, in contrast to reports indicating that 10t12c-18:2 was not detected in human plasma after intake of equal weights of 9c11t-18:2 and 10t12c-18:2 (11, 19, 20) . These opposing results may be due to the different methods used for analysis of CLA. To examine this further, the sodium methoxide and TMSN 2CH3 method used in this study was compared with the boron trifluoride method used in the previous reports, and the Supelcowax-10 GC column used in this study was compared with the Cp-Sil 88 GC column used previously. The levels of 9c11t-18:2, 10t12c-18:2 and total CLA were as much as 10% lower with use of boron trifluoride compared with sodium methoxide and TMSN 2CH3, but the difference was not significant ( Table 6 ). The levels of 9c11t-18:2 and total CLA measured using the CP-Sil 88 GC column were also significantly lower than those measured with the Supelcowax-10 GC column. The amount of CLA measured using the methods in this study was about 1.8-fold higher than that measured using the previous method, which suggests that the contradictory results are due to difference of CLA methylation and the GC column.
In this study, the CLA concentration in blood after ingestion of CLA (about 2 g/d) was 36 mol/L (Table  2 ). This is a functional CLA concentration based on cell culture and animal experiments, since tumor cell proliferation is inhibited by exposure to 20 mol/L CLA (21, 22, 23) . Therefore, CLA ingestion of 2 g/d might have a cancer preventive effect. The CLA concentration in blood was 14 mol/L at 1 wk after completion of CLA ingestion (Table 2) , with a significant decrease over the 1 wk period (Fig. 1) . This suggests that exertion of the preventive effect will require CLA to be taken continuously.
The CLA distribution in blood was examined based on the concentration in RBCs, plasma, and each lipoprotein (Table 3 and 4). The CLA distribution before and just after CLA ingestion was not skewed to any particular blood component, but the CLA ratio in RBCs was significantly higher at 1 wk after the end of CLA ingestion. This suggests that the retention rate of CLA in RBCs is higher than those in other blood components. Close investigation of the retention rate of CLA in RBCs, plasma, VLDL, LDL, and HDL at 1 wk after CLA intake ( Fig. 1) showed significantly higher retention in RBCs compared with that in plasma. Thus, CLA in RBCs is not eliminated as easily as from other blood compo- nents. The lifespan of RBCs is 90-120 d from production and longer than that of lipoproteins (24). Additionally, the fatty acid is not metabolized in the RBC. Therefore, CLA may be able to remain in the RBC membrane for longer than in lipoproteins.
The level of 10t12c-18:2 in plasma decreased faster than that of 9c11t-18:2 ( Fig. 1) , which indicates faster metabolism of 10t12c-18:2 in vivo. However, there was no significant difference in the retention rates of 9c11t-18:2 and 10t12c-18:2 in RBCs. Previous studies have shown that little 10t12c-18:2 accumulated in animals fed equal weights of 9c11t-18:2 and 10t12c-18:2 (8-10), which was proposed to be due to faster metabolism (fatty acid ␤ oxidation) and oxidation (auto-oxidation) of 10t12c-18:2 compared with 9c11t-18:2 (25, 26). Our results suggest that faster metabolism of 10t12c-18:2, rather than faster auto-oxidation, is more important because the retention rates of the two isomers did not differ significantly in RBCs.
Our results showed no influence of CLA ingestion on biochemical parameters in plasma (Table 5 ). An effect of CLA in improving lipid metabolism has been reported in humans (19, (27) (28) (29) , although other reports have not reached this conclusion (5-7, 30, 31) . In our study, this effect may not have been evident because of the low CLA intake level, the short period of CLA ingestion, and the use of healthy subjects. Additionally, it was reported that CLA induces the insulin resistance (31, 32). The cause of this side effect was an overdose of 10t12c-CLA. It is a big problem to clarify the relation to the dosage of CLA isomer, the profitable effect, and the side effect. It is important to examine a safe and a profitable intake method for the CLA isomer in the future. Thus, the effect of CLA on lipid metabolism requires examination in a further study. 
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